Santa Farma, one of the deep-rooted pharmaceutical companies in Turkey, celebrates its 75 th anniversary
Growing with the mission of “Offering healthy services for health” since its inception, Santa Farma, one of Turkey's most established and strong domestic pharmaceutical companies, is celebrating its 75 th year. Moving forward with the goal of increasing access to healthcare through innovative solutions both in Turkey and across the globe, the company aims to ensure that the world's leading pharmaceutical companies manufacture their products in Turkey through its new and modern premises.
Founded in 1944, Santa Farma, one of the most well-established pharmaceutical companies in Turkey that operates under 10 therapeutic categories and with a total of 73 products across 50 markets under these categories is celebrating today its 75th anniversary. The Company's primary objectives in 2019 include evaluating its existing product portfolio in line with its goal of maintaining both its local and global positions, making a difference with new products, expanding to new geographies and moving its local experience to a global scale.
Positioning itself as a strategic partner in domestic production through its investments, Santa Farma enters into partnership with companies that make a difference in the pharmaceuticals manufacturing industry with its cutting-edge manufacturing premises and its team showing a meticulous approach to its work. The company's objective is to ensure that the world's leading pharmaceutical companies manufacture their products in Turkey through its new and modern premises.
Increasing the number of its business partners in the area of import that will open up new markets for the company, Santa Farma set its target to become the champion of exports among Turkish pharmaceuticals companies in 2024 when the company will be celebrating its 80th anniversary. The other expected area of championship is becoming the most favoured pharmaceuticals company in Turkey across the pharmaceuticals industry. With its cultural transformation accelerated by virtue of its 75 th anniversary, Santa Farma continues its efforts to become a leading employer brand for its employees that keep an optimum balance between institutionalization and being a family company. Capacity to manufacture 150 million boxes in a single shift The manufacturing premise of company that was commissioned at the end of 2015 with an investment of EUR 150 millions has a capacity to manufacture 150 million boxes in a single shift. Having acquired in June 2015 its production license and GMP (Good Manufacturing Practices) certificate from the Ministry of Health of Republic of Turkey, the company acquired in 2016 its EU-GMP certificate (European Union Compliance with Good Manufacturing Practices) and ISO 9001:2015, ISO 14001:2015 and OHSAS 18001:2007 certificates in July 2017.
45 full-time employees work in Santa Farma R&D Center, which operates over an established area of approx. 3 thousand sqm. Investing approx. 21 percent more in R&D compared to the previous year, Santa Farma allocates approx. 2 percent of its turnover in 2018 to R&D activities and aims to develop strategic products that can meet the needs of the society and contribute to the national economy through its R&D activities.
Noting that the pharmaceuticals industry is based on the dynamics of innovation and difference and is a highly strategic industry from the perspective of national economy, Mr. Erol Kiresepi, Chairman and CEO of Santa Farma says: “Becoming the first generic in any therapeutic field is golden for our industry and country. We should inevitably focus on R&D and innovation further in order to increase the level of our country to the level of developed countries. At Santa Farma, we determined a vision for Turkey's goal of becoming a global pharmaceutical R&D and manufacturing center. We planned all our investments and moves accordingly. This lies beneath our investment in the manufacturing premises extending over 80 thousand sqm in Dilovası GEBKİM OIZ and R&D Center. One of the key components of our export-oriented growth strategy was to realize these large-scale investments”.
Cookies are used on our website to enhance your user experience and provide you with personalized services. By clicking the "Accept All" option, you consent to the processing of cookies and their sharing with third parties as outlined on the Privacy Policy page.